Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
Rhea-AI Summary
Impact BioMedical (NYSE American: IBO) disclosed that its Form 10-K for the year ended December 31, 2025, filed March 11, 2026, includes an audit opinion from Grassi & Co. with a going concern qualification. The company said this public notice complies with NYSE American Section 610(b) and does not amend its 2025 financial statements. Separately, Impact BioMedical continues strategic plans to merge with Dr. Ashley’s with a projected completion date of July 1, 2026.
Positive
- Merger timeline set for completion by July 1, 2026
- Disclosure compliance with NYSE American Section 610(b)
Negative
- Going concern audit qualification noted in 2025 Form 10-K
- Audit opinion may signal material uncertainty about near-term viability
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | Strategic merger announcement | Positive | +344.6% | Reverse merger agreement with Dr Ashleys to form new NYSE American entity. |
| Feb 26 | Strategic acquisition | Positive | +2.7% | All‑equity acquisition of Celios air purification technology to expand portfolio. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past acquisition/merger headlines for IBO have coincided with positive price reactions, including one very large move after the initial Dr Ashleys merger announcement.
Recent history for Impact BioMedical centers on strategic transactions. A Feb 26, 2025 acquisition of Celios in an all‑equity deal produced a modest positive move. On Jun 23, 2025, the announced strategic reverse merger with Dr Ashleys led to a very large gain of 344.63%. Today’s update reiterates a going concern audit qualification while confirming plans to complete the Dr Ashleys merger by July 1, 2026, extending this M&A narrative.
Key Terms
going concern financial
10-K regulatory
form 10-K regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi & Co., CPAs, P.C. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company’s financial statements for the year ended December 31, 2025.
Again, this announcement does not represent any change or amendment to the Company’s financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2025.
Separately, Impact Biomedical continues with strategic plans to merge with Dr. Ashley’s Ltd. (here), projected to be completed by July 1, 2026.
About Impact Biomedical Inc.
Impact Biomedical Inc. (IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.
Safe Harbor Statement
This press release contains forward-looking statements. These statements involve risks and uncertainties, including the company's ability to close its pending merger and secure additional financing to address the going concern doubt expressed by its auditors. Actual results may differ materially.
Investor Relations:
info@impactbiomedinc.com
